Matched case control analysis of breast cancer specific factors impacting risk of developing SARS-Cov-2 infection.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18579-e18579
Author(s):  
Joanna Zurko ◽  
Aniko Szabo ◽  
Yee Chung Cheng ◽  
Sailaja Kamaraju ◽  
John Burfeind ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Logistic Regression ◽  
Triple Negative ◽  
Case Control Study ◽  
Conditional Logistic Regression ◽  
Case Control ◽  
Control Analysis ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

e18579 Background: Patients with cancer have increased risk of developing SARS-Cov-2 (COVID-19) infection. It is unknown if characteristics related to breast cancer increase the risk of COVID-19 infection. In this retrospective matched case control study, we aim to identify breast cancer related risk factors associated with developing COVID-19 and describe outcomes of patients with breast cancer diagnosed with COVID-19. Methods: Women with breast cancer treated at the Medical College of Wisconsin and diagnosed with COVID-19 between March and December 2020 served as cases. Women with breast cancer without COVID-19 diagnosis within the same time frame were identified as potential controls. Controls were chosen by matching for age (≥60 vs <60), obesity (BMI <30 vs ≥30), county (Milwaukee vs suburban), race (white vs non-white) and diabetes mellitus (DM) with 3:1 matching planned. Univariate comparisons between cases and controls were done via Rao-Scott stratified chi-square test for categorical outcomes and stratified t-test for continuous variables. Conditional logistic regression was done to evaluate the joint effect of multiple characteristics on the odds of being a COVID-19 case. Results: Twenty-five cases and 77 controls were identified. All cases were fully matched by age, obesity, county, and race with 3 cases not able to be matched for DM. Mean age was 54.6 vs 54.9 (p=0.88), BMI 31.0 vs 31.6 (p=0.69), 48% lived in Milwaukee county and 68% were white (cases 24% black & 8% American Indian; controls 32% black). Regarding COVID outcomes, 24.0% (n=6) of cases were hospitalized, median length of stay was 2 days, 8% (n=2) needed oxygen, 4% (n=1) were intubated and 4% (n=1) died due to COVID-19. COVID-19 led to treatment delays in 40% of cases. On univariate analysis of cases vs controls, 64 vs 75% were ER/PR+ (p=0.31), 6.5 vs 5.2% HER2+ (p=0.34), and 9.0 vs 4.2% triple negative (p=0.10). There were no significant differences in breast cancer stage. At time of COVID diagnosis (or last clinic contact if control), 16 vs 14% had active disease (p=0.81), 72 vs 74% were on active treatment (p=0.85), with 21 vs 4% being on chemotherapy (p=0.007), and 44 vs 52% on endocrine therapy (p=0.49). On conditional logistic regression, being on active chemotherapy (OR 5.8, p=0.043) significantly increased the likelihood of developing COVID with a trend seen for triple negative disease (OR 2.8, p=0.12). Conclusions: In this matched case control study of patients with breast cancer, active chemotherapy was significantly associated with an increased likelihood of developing COVID-19 with a trend seen for triple negative disease. Rates of death due to COVID-19 were overall low. Our analysis was limited by small numbers and an inability to fully match patients for DM. These findings support continued strict precautions for those on active chemotherapy and warrants further analysis in those with triple negative disease.

scholarly journals 717. Antibiotic treatment of Shiga toxin-producing Escherichia coli related gastroenteritis and the risk of hemolytic uremic syndrome: a population based matched case-control study in Japan

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S409-S410
Author(s):  
Shota Myojin ◽  
Kyongsun Pak ◽  
Mayumi Sako ◽  
Tohru Kobayashi ◽  
Takuri Takahashi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Shiga Toxin ◽  
Case Control Study ◽  
Conditional Logistic Regression ◽  
Population Based ◽  
Case Control ◽  
Age Group ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

Abstract Background The role of therapeutic intervention, particularly antibiotics, for Shiga toxin-producing Escherichia coli (STEC) related infection is controversial. Methods We performed a population based matched case-control study to assess the association between treatment (antibiotics, antidiarrheal agents and probiotics) for STEC related infections and HUS development. We identified all STEC HUS patients as cases and matched five non-HUS patients as controls using the data from the National Epidemiological Surveillance of Infectious Diseases (NESID) between January 1, 2017, and December 31, 2018. Further medical information was obtained by standardized questionnaires answered by physicians who registered each patient. We used multivariate conditional logistic regression model to evaluate the association between exposures (use of antibiotics, use of antidiarrheal agents, days between disease onset and fosfomycin administration [within two or three days]) and the development of HUS, by matched odds ratios (OR) and 95% confidence intervals (CI). Covariates we used were sex, age group, area code, presence of diarrhea and other factors. We also performed subgroup analyses using age (adults and children) as a stratification factor. Results 7,760 STEC related patients were registered in the NESID. We selected patients who had a record of HUS diagnosis (n=182) and matched controls without HUS (n=910). After collecting standardized paper-based questionnaires, we enrolled 90 HUS patients and 371 non-HUS patients for analysis. In the main analysis, matched OR of fosfomycin was 0.75(0.47-1.20) in all ages, 1.41(0.51-3.88) in adults and 0.58(0.34-1.01) in children. Matched OR of antidiarrheal agents was 2.07(1.07-4.03) in all ages, 1.84(0.32-10.53) in adults, 2.65(1.21-5.82) in children. Matched OR of probiotics was 0.86(0.46-1.61) in all ages, 0.76(0.21-2.71) in adults, 1.00(0.48-2.09) in children. There was no significant association between the timing of fosfomycin use in the first two or five days of illness and HUS development in any age group. Conclusion Our results suggest that fosfomycin might decrease the risk of HUS in children younger than 15 years of age with STEC confirmed bacterial gastroenteritis. Disclosures All Authors: No reported disclosures

Light at Night Exposure and Breast Cancer Risk: A Matched Case-Control Study in England

2018 ◽  
Vol 2017 (1) ◽  
pp. 851
Author(s):  
Susan Hodgson ◽  
Anna Freni Sterrantino ◽  
Alianore Descours ◽  
Amanda Cross ◽  
Adi McCrea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Light At Night ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals Erratum: Associations between Dietary Allium Vegetables and Risk of Breast Cancer: A Hospital-Based Matched Case-Control Study

2018 ◽  
Vol 21 (2) ◽  
pp. 231 ◽  
Author(s):  
Ali Pourzand ◽  
Aynaz Tajaddini ◽  
Saeed Pirouzpanah ◽  
Mohammad Asghari-Jafarabadi ◽  
Nasser Samadi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Allium Vegetables ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

scholarly journals In-Hospital Transfer Is a Risk Factor for Invasive Filamentous Fungal Infection among Hospitalized Patients with Hematological Malignancies: A Matched Case-Control Study

2015 ◽  
Vol 36 (3) ◽  
pp. 320-328 ◽  
Author(s):  
Angèle Gayet-Ageron ◽  
Anne Iten ◽  
Christian van Delden ◽  
Natacha Farquet ◽  
Stavroula Masouridi-Levrat ◽  
...  
Keyword(s):  
Risk Factors ◽  
Fungal Infection ◽  
Hematological Malignancies ◽  
Case Control Study ◽  
Conditional Logistic Regression ◽  
Case Control ◽  
Care Process ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

OBJECTIVEImmunocompromised patients now benefit from a longer life expectancy due to advanced medical techniques, but they are also weakened by aggressive treatment approaches and are at high risk for invasive fungal disease. We determined risk factors associated with an outbreak of invasive filamentous fungal infection (IFFI) among hospitalized hemato-oncological patients.METHODSA retrospective, matched, case-control study was conducted between January 1, 2009, and April 31, 2011, including 29 cases (6 proven, 8 probable, and 15 possible) of IFFI and 102 matched control patients hospitalized during the same time period. Control patients were identified from the hospital electronic database. Conditional logistic regression was performed to identify independent risk factors for IFFI.RESULTSOverall mortality associated with IFFI was 20.7% (8.0%–39.7%). Myelodysplastic syndrome was associated with a higher risk for IFFI compared to chronic hematological malignancies. After adjustment for major risk factors and confounders, >5 patient transfers outside the protected environment of the hematology ward increased the IFFI risk by 6.1-fold. The risk increased by 6.7-fold when transfers were performed during neutropenia.CONCLUSIONThis IFFI outbreak was characterized by a strong association with exposure to the unprotected environment outside the hematology ward during patient transfer. The independent associations of a high number of transfers with the presence of neutropenia suggest that affected patients were probably not sufficiently protected during transport in the corridors. Our study highlights that a heightened awareness of the need for preventive measures during the entire care process of at-risk patients should be promoted among healthcare workers.Infect Control Hosp Epidemiol 2014;00(0): 1–9

Risk factors for sporadic infection withSalmonellaInfantis: a matched case-control study

2013 ◽  
Vol 142 (4) ◽  
pp. 820-825 ◽  
Author(s):  
R. BASSAL ◽  
A. REISFELD ◽  
I. NISSAN ◽  
V. AGMON ◽  
D. TARAN ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Protective Factor ◽  
Case Control Study ◽  
Tap Water ◽  
Conditional Logistic Regression ◽  
Case Control ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Control Study

SUMMARYThis matched case-control study investigated the risk factors for sporadicSalmonellaInfantis infection in 263 affected children and 263 age-, gender- and neighbourhood-matched controls. Information about exposure to potential risk factors was obtained via telephone interview and evaluated by conditional logistic regression analysis. Age groups ⩽1 year (n = 77) and >1 year (n = 186) were analysed separately. Of those aged ⩽1 year, breastfeeding was a significant protective factor against infection [matched odds ratio (mOR) 0·24, 95% confidence interval (CI) 0·10–0·59,P < 0·01]. In the older group, consumption of eggs (mOR 1·87, 95% CI 1·00–3·49,P = 0·05) was a significant risk factor and thawing chicken in water (mOR 2·55, 95% CI 0·94–6·91,P = 0·07) was borderline risk factor, while consumption of carrots (mOR 0·46, 95% CI 0·26–0·83,P < 0·01), drinking tap water (mOR 0·44, 95% CI 0·22–0·85,P = 0·02), religious lifestyle (mOR 0·40, 95% CI 0·21–0·74,P < 0·01) and having a high number of children in the household (mOR 0·72, 95% CI 0·58–0·88,P < 0·01) were significant protective factors. Consumers should avoid eating undercooked eggs and food handlers should be educated regarding proper handling and cooking of eggs. Breastfeeding should be strongly encouraged by public health authorities. The public must be educated on stringent hygiene practices, especially proper cooking of eggs to reduce infection rates.

scholarly journals Dose-specific effectiveness of 7- and 13-valent pneumococcal conjugate vaccines against vaccine-serotype Streptococcus pneumoniae colonization: a matched, case-control study

2019 ◽  
Author(s):  
Joseph A. Lewnard ◽  
Noga Givon-Lavi ◽  
Ron Dagan
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Control Analysis ◽  
Reduced Dose ◽  
Pneumococcal Carriage ◽  
Matched Case ◽  
Case Control Analysis ◽  
To Receive ◽  
Matched Case Control Study ◽  
Control Study

ABSTRACTBackgroundReduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideration in countries where children are currently recommended to receive three PCV doses. However, dose-specific PCV effectiveness against vaccine-serotype colonization is uncertain.MethodsFrom 2009-2016, we conducted surveillance of pneumococcal carriage in southern Israel, where PCV is administered at ages 2, 4, and 12 months (2+1 schedule). We obtained nasopharyngeal swabs and vaccination histories from 4245 children ages 0-59 months without symptoms of diseases that could be caused by pneumococci. In a case-control analysis, we measured protection against vaccine-serotype colonization as one minus the matched odds ratio for PCV doses received.ResultsAt ages 5-12 months, a second PCV7/13 dose increased protection against PCV7-serotype carriage from –23.6% (95%CI: –209.7-39.1%) to 27.1% (–69.2-64.5%), and a second PCV13 dose increased protection against carriage of all PCV13 serotypes from –54.8% (–404.3-39.1%) to 23.4% (– 128.5-67.1%). At ages 13-24 months, a third PCV7/13 dose increased protection against PCV7-serotype carriage from 32.4% (–8.4-58.0%) to 74.1% (58.4-84.6%), and a third PCV13 dose increased protection against carriage of all PCV13 serotypes from –50.0% (–194.0-42.7%) to 49.7% (15.8-83.3%). On average, each PCV13 dose conferred 37.7% (7.0-61.8%) greater protection against carriage of serotypes 1, 5, 6A, 7F, and 19A than carriage of serotype 3. PCV13-derived protection against carriage of serotypes 1, 5, 6A, 7F, and 19A was equivalent to PCV7/13-derived protection against carriage of PCV7 serotypes.ConclusionsIn a setting implementing a 2+1 PCV schedule, protection against vaccine-serotype colonization is sustained primarily by the third dose.

Sign in / Sign up

Export Citation Format

Share Document